CAR-T Cell Therapy

Introduction

CAR-T cell therapy is one of the newer ways doctors treat certain blood cancers. It is used most often when a cancer has come back after earlier treatment or has not responded to the usual options. If your oncology team has raised CAR-T as a possibility, you are likely already living with a diagnosis such as a lymphoma, leukaemia, or multiple myeloma, and you are now trying to understand what this treatment involves before you and your doctors decide on the next step.

This guide explains what CAR-T cell therapy is, how it works, who it is currently used for, what the treatment journey looks like from cell collection through infusion and recovery, and the side effects that are unique to this kind of therapy. It is written in plain language and is meant to help you have a clearer conversation with your haematology and oncology team. Decisions about whether CAR-T is right for your situation, and which product to use, are clinical ones that depend on your cancer type, your prior treatments, your overall health, and the centre where you are being treated.

What Is CAR-T Cell Therapy?

CAR-T cell therapy stands for chimeric antigen receptor T-cell therapy. It is a type of cancer immunotherapy, which means it uses the body’s own immune system to fight cancer rather than using chemotherapy drugs or radiation to kill cancer cells directly.

T cells are a kind of white blood cell. They are part of your immune system and normally help your body recognise and destroy infected or abnormal cells. In many cancers, however, the cancer cells either hide from T cells or weaken the T cells’ ability to attack them.

In CAR-T cell therapy, doctors take some of your own T cells out of your blood and send them to a specialised laboratory. There, the cells are genetically modified so that they carry a new structure on their surface called a chimeric antigen receptor, or CAR. This receptor is designed to recognise a specific marker (called an antigen) that is found on the surface of the cancer cells. The most common target so far is a marker called CD19, which is found on many B-cell cancers. For multiple myeloma, the target is usually BCMA.

Once the modified T cells are grown into large numbers, they are infused back into your bloodstream. The engineered cells then find the cancer cells, attach to them through the new receptor, and destroy them. Because the T cells can multiply inside your body, even a single infusion can lead to a long-lasting effect.

Step 1: Collecting your T cells (leukapheresis)

The process begins with a procedure called leukapheresis. Blood is drawn from a vein, usually through a large IV line or a central line, and passed through a machine that separates out the white blood cells, including T cells. The rest of the blood is returned to your body. This step typically takes a few hours and is done as an outpatient procedure.

Step 2: Engineering the cells in the laboratory

Your collected T cells are sent to a specialised manufacturing facility. There, a harmless modified virus is used to insert a new gene into the T cells. This gene tells the cells to make the chimeric antigen receptor on their surface. The new receptor is built to recognise the specific marker on the cancer cells.

Step 3: Growing the cells

The engineered T cells are then multiplied in the laboratory until there are millions of them. This step usually takes between two and four weeks, depending on the product and the manufacturing process.

Step 4: Bridging therapy (if needed)

While your cells are being manufactured, your doctors may give you additional chemotherapy or other treatment to keep the cancer under control. This is called bridging therapy. Not every patient needs it; it depends on how active the cancer is during the waiting period.

Step 5: Conditioning chemotherapy (lymphodepletion)

A few days before your CAR-T cells are infused, you will receive a short course of chemotherapy. This is called lymphodepletion. Its purpose is not to treat the cancer directly but to reduce the number of existing immune cells in your body, which gives the new CAR-T cells space to expand and work. The conditioning chemotherapy is usually given over three to five days.

Step 6: Infusion of CAR-T cells

The engineered cells are then given to you through an IV, similar to a blood transfusion. The infusion itself usually takes between thirty minutes and an hour or two. It is not painful, but you will be monitored closely during and after the infusion.

Step 7: Monitoring and recovery

After the infusion, the CAR-T cells begin to multiply inside your body and attack the cancer cells. This is also the period when the most distinctive side effects of CAR-T therapy can appear. Most patients are admitted to hospital, or kept under very close outpatient observation, for at least the first one to two weeks.

Who Is CAR-T Cell Therapy Used For?

CAR-T cell therapy is currently used mainly for certain blood cancers. Approval in different countries has expanded over the past few years, but the core indications are similar across major regulators. CAR-T products are usually considered when a cancer has come back after one or more lines of standard treatment (called relapsed disease) or has not responded well to those treatments (called refractory disease). For some indications, CAR-T is now being used earlier in the treatment path based on recent clinical trial results.

B-cell lymphomas

CAR-T cell therapy is widely used for several types of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and transformed follicular lymphoma. It is also used for follicular lymphoma and mantle cell lymphoma that have returned or not responded to standard therapy.

Acute lymphoblastic leukaemia (ALL)

CAR-T cell therapy is used for B-cell acute lymphoblastic leukaemia, particularly in children and young adults whose disease has come back or not responded to chemotherapy.

Multiple myeloma

For multiple myeloma, CAR-T products that target BCMA are used when the disease has come back after several other treatments, including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies.

Chronic lymphocytic leukaemia (CLL)

CAR-T cell therapy has been approved for certain patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma whose disease has progressed after specific targeted treatments.

Other cancers and research

Research is active in expanding CAR-T therapy to other blood cancers and to some solid tumours, but outside the indications above, CAR-T is generally available only as part of a clinical trial.

Eligibility for CAR-T is a clinical decision made by your haematology and oncology team. It depends on the type of cancer, the marker it carries (for example, whether the cancer cells express CD19 or BCMA), how the disease has behaved with earlier treatments, your overall health, the function of your heart, lungs, kidneys, and liver, and whether your blood counts and infections are under reasonable control.

Types of CAR-T Cell Therapy

Several CAR-T products have been approved internationally. They differ in the cancer marker they target, the structure of the receptor they carry, and the patient groups they are approved for. The major categories that patients will hear about include:

• CD19-directed CAR-T products — used for B-cell lymphomas, B-cell ALL, and CLL. These are the most established CAR-T therapies.
• BCMA-directed CAR-T products — used for multiple myeloma.
• Autologous CAR-T — the type described throughout this article, where your own T cells are collected, modified, and given back. All currently approved CAR-T therapies are autologous.
• Allogeneic (“off-the-shelf”) CAR-T — a research approach using T cells from a healthy donor. This is not yet a standard treatment but is being studied.

In India, the Central Drugs Standard Control Organisation (CDSCO) approved the country’s first indigenously developed CAR-T product, a CD19-directed therapy, in October 2023 for B-cell lymphomas and B-cell ALL. International CAR-T products are also accessed at selected centres. Which product is appropriate depends on your specific cancer type, prior treatments, and the centre’s programme.

The Treatment Plan and What to Expect

CAR-T cell therapy is not a single appointment. It is a structured programme that usually unfolds over several weeks, and most of it takes place at a specialised cancer centre with experience in cellular therapy.

Before treatment: evaluation and counselling

Before CAR-T is offered, you will go through a detailed evaluation. This typically includes:

• A full review of your cancer history and previous treatments
• Blood tests including blood counts, kidney and liver function, infection screening (such as for hepatitis B, hepatitis C, HIV, and tuberculosis)
• Bone marrow biopsy, if relevant to your cancer type
• Imaging studies such as CT or PET-CT scans
• Heart tests such as an ECG and echocardiogram
• Lung function tests
• A neurological baseline assessment

You and your family will also have detailed discussions with the cellular therapy team about how the treatment works, what the side effects can be, and what to expect during and after the infusion. A designated caregiver is usually required for the first several weeks because the side effects can include confusion or other changes that you may not notice in yourself.

The leukapheresis day

On the day of cell collection, you will spend several hours connected to the apheresis machine. Most people find it manageable, although some feel cold, light-headed, or tingly because of the way blood calcium levels shift during the procedure. The team monitors and adjusts for this throughout.

The waiting period

After collection, your cells are sent for manufacturing. This is typically two to four weeks but can be longer. During this time, your oncology team continues to monitor you and may give bridging therapy if your cancer needs to be controlled.

Conditioning and infusion

You will then be admitted (or attend daily) for the lymphodepleting chemotherapy, followed a few days later by the CAR-T infusion itself. The infusion day is usually short and uneventful, but it marks the start of the most intensive monitoring period.

Hospitalisation and close monitoring

Most centres keep CAR-T patients in hospital for at least the first one to two weeks after infusion, because the major side effects tend to appear in this window. Even after discharge, you will be asked to stay close to the treatment centre, often within a short travel distance, for several more weeks. International patients are usually advised to plan for around six to eight weeks of stay near the centre in total, though the exact length depends on how you respond.

Caregiver requirements

A reliable caregiver is essential. They will need to stay with you, recognise early warning signs (such as fever, confusion, or trouble speaking), and bring you back to the centre quickly if anything changes. Centres usually train caregivers in detail before discharge.

Side Effects and How They Are Managed

CAR-T cell therapy is highly active treatment and has side effects that are different from those of chemotherapy. Some are unique to cellular therapy. Understanding them in advance helps you and your caregiver respond quickly, which is the single most important factor in keeping them under control.

Cytokine release syndrome (CRS)

Symptoms of CRS can include:

• High fever
• Low blood pressure
• Fast heart rate
• Difficulty breathing or low oxygen levels
• Muscle aches and severe fatigue
• Nausea

CRS usually begins within the first few days after infusion, although the exact timing depends on the product. Doctors grade CRS by severity using a consensus system from the American Society for Transplantation and Cellular Therapy (ASTCT). Mild cases are managed with fluids and supportive care. Moderate to severe cases are treated with a medication called tocilizumab, which blocks one of the main cytokines (IL-6) involved, and sometimes with steroids. Severe cases may need treatment in an intensive care unit.

Immune effector cell-associated neurotoxicity syndrome (ICANS)

• Confusion or disorientation
• Difficulty finding words or speaking clearly
• Tremors
• Drowsiness
• Headache
• Seizures (rare)

ICANS is monitored using a simple bedside test that checks orientation, naming, writing, and attention. Treatment usually involves steroids and supportive care. Most cases resolve, although the recovery can take days to weeks.

Low blood counts (cytopenias)

Both the conditioning chemotherapy and the action of the CAR-T cells reduce normal blood cells. You may have low red cell counts (causing anaemia and fatigue), low platelets (raising the risk of bruising and bleeding), and low white cells (raising infection risk). Some patients need transfusions or growth factor injections during recovery. Blood counts usually improve over weeks to months, although in some patients the recovery is slow.

Infections

Because both your normal immune cells and (in CD19-directed therapy) your B cells are reduced, infections are a real risk during recovery. Common precautions include antiviral, antibacterial, and sometimes antifungal medications, careful hand and food hygiene, avoiding crowded places, and prompt evaluation of any fever. Some patients need immunoglobulin replacement therapy (IVIG) for a period if antibody levels stay low.

B-cell aplasia and hypogammaglobulinaemia

CD19-directed CAR-T cells destroy not only cancerous B cells but also healthy B cells, which produce antibodies. This can leave you with low antibody levels for months. Your team will monitor this and may use IVIG to reduce infection risk.

Tumour lysis syndrome

When a large amount of cancer is destroyed quickly, the breakdown products can affect the kidneys and the body’s salt balance. This is treated with hydration, medications, and close monitoring of blood tests.

Later effects

Most acute side effects resolve within the first month or two. Longer-term concerns include prolonged low blood counts, ongoing risk of infection, and the small possibility of late effects from the genetic modification process. Regulators have asked for long-term follow-up of CAR-T patients to track these issues.

Response and Monitoring

Doctors begin assessing the response to CAR-T cell therapy soon after infusion and continue to monitor it for years afterwards.

Early assessment

The first formal response assessment is usually done about one month after infusion. For lymphomas, this typically involves a PET-CT scan. For leukaemia, it involves a bone marrow biopsy and tests that look for very small amounts of remaining disease (called minimal residual disease, or MRD). For multiple myeloma, it involves blood and urine tests for the abnormal protein and often a bone marrow assessment.

What the responses mean

Possible outcomes include:

• Complete response — no detectable cancer on standard tests
• Partial response — the cancer has shrunk significantly but is still present
• Stable disease — the cancer is neither shrinking nor growing meaningfully
• Progression — the cancer is growing, indicating that CAR-T has not controlled it

Long-term monitoring

After the first assessment, follow-up scans, blood tests, and bone marrow tests continue at regular intervals, usually every three months at first, then less frequently. Long-term follow-up also tracks blood counts, antibody levels, infections, and any late effects.

What to expect from outcomes

In clinical trials, CAR-T cell therapy has produced complete responses in a significant proportion of patients with relapsed or refractory blood cancers that previously had limited options. In some patients, the response has been durable for years, raising the possibility of long-term disease control. In others, the cancer comes back after a period of response, and additional treatment may be needed. Your own likely outcome depends on the specific disease, how much cancer is present when CAR-T is given, prior treatments, and your overall health. Honest, personalised estimates can only come from your treating team.

Combining with Other Treatments

CAR-T cell therapy does not replace all other cancer treatments. It fits into a broader plan that often includes other modalities.

Before CAR-T

Most patients receiving CAR-T have already had several lines of treatment, which may include chemotherapy, immunotherapy with monoclonal antibodies, targeted therapies, radiation, or stem cell transplant. Bridging therapy may be used to control the cancer while CAR-T cells are being manufactured.

After CAR-T

Depending on the response, doctors may follow CAR-T with maintenance treatment, additional targeted therapy, or in selected situations a stem cell transplant. If the cancer comes back, options may include further therapy with a different mechanism, clinical trials of newer CAR-T constructs, or other approaches.

CAR-T compared with stem cell transplant

Both CAR-T cell therapy and autologous or allogeneic stem cell transplant are intensive treatments used in advanced blood cancers. They work differently. Transplant uses high-dose chemotherapy followed by infusion of stem cells to rebuild the bone marrow. CAR-T uses engineered immune cells to attack cancer directly. For some cancers, such as relapsed large B-cell lymphoma, current guidance from groups including NCCN and ESMO positions CAR-T as a preferred option ahead of transplant in selected patients, based on recent trial results. The choice between, or sequence of, these treatments is highly individual.

Living During and After Treatment

The CAR-T journey affects daily life well beyond the infusion day.

During treatment and early recovery

Expect significant fatigue, reduced appetite, and emotional ups and downs. Most patients are not able to work or carry out normal activities during the first month or two. Driving is usually not allowed for at least eight weeks after infusion because of the risk of neurological side effects.

Infection precautions

For several months after CAR-T, you will need to be careful about infections. Common precautions include:

• Avoiding crowds and people with active infections
• Practising careful hand hygiene
• Following food safety guidance (for example, avoiding undercooked food)
• Continuing prescribed antimicrobial medications
• Discussing vaccinations with your team — live vaccines are usually avoided for a period, and re-vaccination schedules vary

Emotional and psychological care

CAR-T cell therapy is physically and emotionally demanding. Anxiety while waiting for cells to be manufactured, fear of side effects, uncertainty about response, and the strain on caregivers are all common. Many cancer centres provide access to psycho-oncology counselling, peer support, and social work. Using these supports is not optional comfort — it is a recognised part of recovery.

Returning to normal life

For patients who respond well, energy and stamina gradually return over months. Work, exercise, and travel are usually possible again, although the timing and intensity should be discussed with your team. Long-term follow-up continues for years.

CAR-T Cell Therapy in Children and Young Adults

CAR-T cell therapy was first approved for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL). This remains one of the most important paediatric uses. For children with B-ALL whose disease has not responded to chemotherapy or has come back after treatment, including after stem cell transplant, CAR-T has produced high rates of complete response in clinical studies and has become a standard option in major guidelines.

Paediatric CAR-T differs from adult CAR-T in a few important ways:

• Cell collection in young children may require a specially adapted apheresis procedure, sometimes under sedation
• Children appear to be at somewhat higher risk of certain side effects such as severe CRS, and centres treating children have specific paediatric intensive care expertise
• Neurotoxicity (ICANS) assessment uses age-appropriate tools, since standard adult tests are not suitable for younger children
• Schooling, growth, fertility, and developmental support are part of long-term follow-up, alongside cancer surveillance
• Family and caregiver involvement is more intensive, and centres typically provide structured support for parents and siblings

For older adolescents and young adults, the treatment process is broadly similar to that for adults, but the long-term considerations — including fertility preservation discussions before treatment, education, and career — are given particular attention.

Decisions about CAR-T in children are made by paediatric haematology-oncology teams in centres with experience in cellular therapy, alongside the family.

Frequently Asked Questions

Is CAR-T cell therapy a cure?

For some patients, CAR-T can lead to long-lasting remission that may continue for years. For others, the cancer returns after a period of response. Whether CAR-T can be considered a cure in any individual case depends on the cancer type, depth of response, and how long the response lasts. Long-term follow-up is essential for everyone.

How long does the whole CAR-T process take?

From the day cells are collected to the end of close monitoring is usually around eight to twelve weeks. Cell manufacturing takes two to four weeks, conditioning chemotherapy takes a few days, the infusion is a single day, and intensive monitoring covers the following several weeks. Long-term follow-up continues for years.

Will I lose my hair?

The CAR-T infusion itself does not cause hair loss. However, the conditioning chemotherapy and earlier treatments may cause temporary hair thinning or loss. Most patients regrow their hair over time.

Can CAR-T be repeated if the cancer comes back?

In selected cases, a second CAR-T infusion is possible, sometimes using a product that targets a different marker on the cancer cells. Whether this is an option depends on the cancer type, why the first treatment did not produce a lasting response, and the patient’s overall condition. Other options such as further chemotherapy, targeted therapy, transplant, or clinical trials are also considered.

Will I be infectious or radioactive after CAR-T?

No. CAR-T cells are your own immune cells; they are not infectious and there is no radioactivity involved. However, because you are at higher risk of infection during recovery, you and those around you will be asked to follow careful hygiene practices for some time.

Why is a caregiver required?

Because side effects such as confusion or fever can come on quickly and you may not notice them in yourself, a trained caregiver is required to stay with you during the high-risk weeks. They watch for warning signs and bring you back to the centre quickly if anything changes. Most centres will not proceed with CAR-T unless a reliable caregiver is in place.

Can I have CAR-T if I have had a stem cell transplant?

Yes, in many situations. CAR-T cell therapy can be given to patients whose cancer has returned after autologous or allogeneic stem cell transplant. Your team will review your specific situation, the time since transplant, your blood counts, and your overall health.

Will CAR-T affect my fertility?

The conditioning chemotherapy and earlier cancer treatments can affect fertility. If fertility is important to you, it should be discussed with your team before treatment starts. Options such as sperm banking or egg or embryo freezing may be considered, depending on age, time available, and clinical situation.

How soon will we know if it worked?

The first formal response assessment is usually done about one month after infusion, with further assessments at three months, six months, and beyond. Some signs of response (such as falling blood markers) may appear earlier, but the picture takes time to become clear.

Conclusion

CAR-T cell therapy is one of the most significant advances in modern cancer treatment for certain blood cancers. By using your own immune cells, redesigned in a laboratory, it offers a way to attack cancer with a level of precision and persistence that earlier treatments could not provide. For patients whose cancer has come back after, or not responded to, standard therapy, CAR-T has changed what is medically possible.

At the same time, CAR-T cell therapy is a complex treatment with a structured process, distinctive side effects, and a recovery that unfolds over weeks and months. It is best delivered in centres with experience in cellular therapy and with strong intensive care and supportive care backup. Whether CAR-T is appropriate for any individual situation, which product to use, and how it fits with other treatments are clinical decisions that depend on the cancer type, prior treatments, overall health, and a careful discussion with your haematology and oncology team.